The pharmacokinetics of the lymphotropic nanoparticle MRI contrast agent ferumoxtran-10
The pharmacokinetics of the lymphotropic nanoparticle MRI contrast agent ferumoxtran-10
复制标题
DOI：
10.3233/cbm-2009-0579
复制
发表时间：
2009-01-01
影响因子：
3.1
通讯作者：
Wolf, Gerald
中科院分区：
文献类型：
--
作者：
Islam, Tina;Wolf, Gerald
ferumoxtrans -10是一种超小超顺磁性可生物降解的氧化铁，可作为MRI造影剂用于区分原发性恶性肿瘤的转移性和非转移性淋巴结，以及吞噬细胞相关疾病过程的成像。阿魏-10是一种冻干粉，含有210毫克铁、631毫克葡聚糖和27毫克柠檬酸钠。氧化铁核决定了ferumoxtrans -10的磁性能，主要是它对MR弛豫时间T1、T2和T2*的影响。右旋糖酐的附着延长了纳米颗粒的循环时间。阿魏酮-10的预期人体剂量为2.6 mg Fe/kg。用生理盐水重新配制并稀释后，通过缓慢滴注的方式静脉注射。颗粒在初始血管分布后，被脾脏、淋巴结、骨髓和肝脏的网状内皮系统细胞缓慢吞噬。当阿魏-10存在于吞噬细胞中时，氧化铁引起局部磁场不均匀，导致质子弛豫率增加，导致t1 /T2中期或重T2加权MR图像的信号丢失。储存在溶酶体中的颗粒最终被降解：铁进入正常的身体铁代谢循环，葡聚糖主要通过肾脏排出。
Ferumoxtran-10 is an ultrasmall superparamagnetic biodegradable iron oxide which serves as a MRI contrast agent in the differentiation of metastatic and non-metastatic lymph nodes in primary malignancies and imaging of phagocyte-associated disease processes. Ferumoxtran-10 is supplied as a lyophilized powder containing 210 mg of iron, 631 mg of dextran, and 27 mg of sodium citrate. The iron oxide core determines the magnetic properties of ferumoxtran-10, primarily its effects on the MR relaxation times, T1, T2, and T2*. Attachment of dextran prolongs the circulatory time of the nanoparticles. The intended human dose of ferumoxtran-10 is 2.6 mg Fe/kg.Reconstituted and diluted with physiological saline it is administered intravenously by means of a slow drip infusion. After initial vascular distribution of the particles, they are slowly phagocytosed by the reticuloendothelial system cells of the spleen, lymph nodes, bone marrow, and liver. When ferumoxtran-10 is present in phagocytic cells the iron oxide causes local magnetic field inhomogeneities which lead to increases in proton relaxation rates, resulting in signal loss on mid-T1/T2 or heavily T2-weighted MR images. Stored in lysosomes the particles are ultimately degraded: the iron enters the normal body iron metabolism cycle and dextran is eliminated mainly via the kidney.